GlassScriptPhysician profile
Steven David Morton
NPI 1891768859
$27,268.16
in general payments reported to CMS, 2019-2025
28 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $2,543 · 2021: $257 · 2022: $334 · 2023: $1,212 · 2024: $1,963 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,396.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $21,053.91 | 2019-2021 | |
| Stryker Corporation | $2,877.80 | 2019-2025 | Mako, Easyfuse, Augment Injectable |
| Depuy Synthes Sales INC. | $655.15 | 2019-2025 | Attune, Monovisc, Velys |
| Smith+Nephew, INC. | $512.43 | 2021-2025 | Bioinductive Implant With Arthroscopic Delivery System - Medium, Evos, K-15 Pork |
| Zimmer Biomet Holdings, INC. | $380.63 | 2019-2020 | |
| Amgen INC. | $379.19 | 2019-2025 | Krystexxa, Prolia, Evenity |
| Elite Orthopedics, LLC | $323.58 | 2019-2025 | |
| Horizon Therapeutics Plc | $286.50 | 2023 | Krystexxa |
| Avanos Medical | $114.65 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $110.19 | 2019-2025 | Euflexxa |
| International Life Sciences | $84.94 | 2024 | Flexband |
| Skeletal Dynamics INC | $77.11 | 2024 | Geminus, Align, Implate |
| Medacta USA, INC. | $48.96 | 2020-2021 | |
| Ossio INC | $40.95 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $38.81 | 2022-2023 | Iovera, Zilretta, Exparel |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $36.77 | 2019-2024 | Exogen Ultrasound Bone Healing System |
| Sanofi-Aventis U.S. LLC | $34.95 | 2019-2020 | |
| Heraeus Medical, LLC. | $26.61 | 2019 | |
| Zyla Life Sciences, INC. | $23.86 | 2019 | |
| Radius Health, INC. | $22.14 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $21.31 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.82 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $20.39 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.02 | 2025 | Caplyta |
| Tela Bio, INC. | $15.87 | 2022 | |
| Baxter Healthcare | $15.31 | 2022 | |
| Lilly USA, LLC | $15.30 | 2024 | Mounjaro |
| Exact Sciences Corporation | $14.01 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Morton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.